Specific recommendations for implantation of each prosthesis , taking into consideration the presence of pre-existent conduction abnormalities and anatomical factors , may be needed to reduce the risk of PPI
Aims The incidence of new-onset conduction abnormalities requiring permanent pacemaker implantation ( PPI ) after transcatheter aortic valve implantation ( TAVI ) with new-generation prostheses remains debated .
This systematic review analyses the incidence of PPI after TAVI  with new-generation devices and evaluates the electrical , anatomical , and procedural factors associated with PPI .
In addition , the incidence of PPI after  TAVI with early generation prostheses was review ed for comparison .
Procedural, 30-day and one year outcome following CoreValve or Edwards transcatheter aortic valve implantation: results of the Belgian national registry.
We report clinical outcomes following transcatheter aortic valve implantation ( TAVI ) , using the CoreValve revalving system ( 18 Fr transfemoral or subclavian ) or the Edwards Sapien valve ( 22 Fr transfemoral or 24 Fr transapical ) as part of a Belgian prospect i ve non-r and omized multicentre registry . All 15 Belgian centres performing TAVI  participated to this registry ( seven exclusively Edwards Sapien , eight exclusively CoreValve ) . All consecutive high-risk symptomatic patients with severe aortic stenosis were evaluated by a heart team and screened for eligibility for TAVI . Three hundred and twenty-eight patients underwent TAVI with CoreValve ( n = 141 ; eight subclavian and 133 transfemoral ) or Edwards Sapien ( n = 187 ; 99 transfemoral and 88 transapical ) up to April 2010 .  Procedural success was 97 % . One-month survival was 88 % for the Edwards and 89 % for the CoreValve treated patients . One-month mortality was both related to cardiac and non-cardiac reasons . Overall one-year survival was 78 % in the CoreValve transfemoral treated patients , 100 % in the CoreValve subclavian treated patients , 82 % in the Edwards transfemoral treated patients and 63 % in the Edwards transapical treated patients . This mid-term mortality was mainly related to age-related , non-cardiac complications
Specific recommendations for implantation of each prosthesis , taking into consideration the presence of pre-existent conduction abnormalities and anatomical factors , may be needed to reduce the risk of PPI
Aims The incidence of new-onset conduction abnormalities requiring permanent pacemaker implantation ( PPI ) after transcatheter aortic valve implantation ( TAVI ) with new-generation prostheses remains debated .
This systematic review analyses the incidence of PPI after TAVI  with new-generation devices and evaluates the electrical , anatomical , and procedural factors associated with PPI .
In addition , the incidence of PPI after  TAVI with early generation prostheses was review ed for comparison .